OBJECTIVE: Hypertension is associated with unfavorable changes in adrenergic receptor responsiveness, but the relationship of race and sex to adrenergic receptor responsiveness in the development of cardiovascular disease is unclear. This study examined α-adrenergic and ß-adrenergic receptor responsiveness in African-American and white men and women with untreated high blood pressure (BP) (HBP) and with normal BP. METHODS AND RESULTS: The study sample comprised 161 African-American and white men and women in the age range 25-45 years. Isoproterenol, a nonselective ß-adrenergic receptor agonist, was administered intravenously to determine the bolus dose required to increase heart rate by 25 bpm, an index of β-adrenergic receptor responsiveness. Similarly, phenylephrine, an α1-adrenergic receptor agonist, was administered to determine the bolus dose required to increase BP by 25 mmHg, an index of vascular α1-adrenergic receptor responsiveness. HBP (P < 0.01), male sex (P = 0.04), and higher BMI (P < 0.01) were all associated with reduced β-adrenergic receptor responsiveness, with a similar trend observed for African-American race (P = 0.07). Conversely, α1-adrenergic receptor responsiveness was increased in association with HBP (P < 0.01), female sex (P < 0.01), and African-American race (P < 0.01). CONCLUSION: In the early stages of hypertension, cardiovascular β-adrenergic receptors demonstrate blunted responsiveness, whereas conversely α1-adrenergic receptors exhibit increased responsiveness. This pattern of receptor changes is especially evident in men and African-Americans, is exacerbated by obesity, and may contribute to the development of cardiovascular disease.
OBJECTIVE:Hypertension is associated with unfavorable changes in adrenergic receptor responsiveness, but the relationship of race and sex to adrenergic receptor responsiveness in the development of cardiovascular disease is unclear. This study examined α-adrenergic and ß-adrenergic receptor responsiveness in African-American and white men and women with untreated high blood pressure (BP) (HBP) and with normal BP. METHODS AND RESULTS: The study sample comprised 161 African-American and white men and women in the age range 25-45 years. Isoproterenol, a nonselective ß-adrenergic receptor agonist, was administered intravenously to determine the bolus dose required to increase heart rate by 25 bpm, an index of β-adrenergic receptor responsiveness. Similarly, phenylephrine, an α1-adrenergic receptor agonist, was administered to determine the bolus dose required to increase BP by 25 mmHg, an index of vascular α1-adrenergic receptor responsiveness. HBP (P < 0.01), male sex (P = 0.04), and higher BMI (P < 0.01) were all associated with reduced β-adrenergic receptor responsiveness, with a similar trend observed for African-American race (P = 0.07). Conversely, α1-adrenergic receptor responsiveness was increased in association with HBP (P < 0.01), female sex (P < 0.01), and African-American race (P < 0.01). CONCLUSION: In the early stages of hypertension, cardiovascular β-adrenergic receptors demonstrate blunted responsiveness, whereas conversely α1-adrenergic receptors exhibit increased responsiveness. This pattern of receptor changes is especially evident in men and African-Americans, is exacerbated by obesity, and may contribute to the development of cardiovascular disease.
Authors: Ajay K Gupta; Neil R Poulter; Joanna Dobson; Sandra Eldridge; Francesco P Cappuccio; Mark Caulfield; David Collier; J Kennedy Cruickshank; Peter S Sever; Gene Feder Journal: Am J Hypertens Date: 2010-08-19 Impact factor: 2.689
Authors: KaMala S Thomas; Richard A Nelesen; Vanessa L Malcarne; Michael G Ziegler; Joel E Dimsdale Journal: Psychosom Med Date: 2006 Sep-Oct Impact factor: 4.312
Authors: Yan Gong; Zhiying Wang; Amber L Beitelshees; Caitrin W McDonough; Taimour Y Langaee; Karen Hall; Siegfried O F Schmidt; Robert W Curry; John G Gums; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: Hypertension Date: 2016-01-04 Impact factor: 10.190
Authors: Andrew Sherwood; Patrick R Steffen; James A Blumenthal; Cynthia Kuhn; Alan L Hinderliter Journal: Am J Hypertens Date: 2002-02 Impact factor: 2.689
Authors: Daniel Kurnik; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein Journal: Hypertension Date: 2007-12-10 Impact factor: 10.190
Authors: Daniel Kurnik; Chun Li; Gbenga G Sofowora; Eitan A Friedman; Mordechai Muszkat; Hong-Guang Xie; Paul A Harris; Scott M Williams; Usha B Nair; Alastair J J Wood; C Michael Stein Journal: Pharmacogenet Genomics Date: 2008-10 Impact factor: 2.089
Authors: LaBarron K Hill; Andrew Sherwood; Maya McNeilly; Norman B Anderson; James A Blumenthal; Alan L Hinderliter Journal: Psychosom Med Date: 2018 Feb/Mar Impact factor: 4.312
Authors: Martin I Sigurdsson; Nathan H Waldron; Andrey V Bortsov; Shad B Smith; William Maixner Journal: J Cardiovasc Pharmacol Date: 2018-03 Impact factor: 3.105
Authors: Andrew Sherwood; LaBarron K Hill; James A Blumenthal; Kirkwood F Adams; Nicola J Paine; Gary G Koch; Christopher M O'Connor; Kristy S Johnson; Alan L Hinderliter Journal: Am Heart J Date: 2017-07-12 Impact factor: 4.749
Authors: Katlyn E McGraw; Daniel W Riggs; Shesh Rai; Ana Navas-Acien; Zhengzhi Xie; Pawel Lorkiewicz; Jordan Lynch; Nagma Zafar; Sathya Krishnasamy; Kira C Taylor; Daniel J Conklin; Andrew P DeFilippis; Sanjay Srivastava; Aruni Bhatnagar Journal: Environ Res Date: 2021-02-24 Impact factor: 6.498
Authors: Yuichiro Yano; Anthony J Viera; Alan L Hinderliter; Lana L Watkins; James A Blumenthal; Kristy S Johnson; LaBarron K Hill; Andrew Sherwood Journal: Am J Hypertens Date: 2020-08-04 Impact factor: 3.080